Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-2-18
pubmed:abstractText
DA-11004 is a synthetic, potent NADP-dependent isocitrate dehydrogenase (IDPc) inhibitor where IC50 for IDPc is 1.49 microM. The purpose of this study was to evaluate the effects of DA-11004 on the high fat high sucrose (HF)-induced obesity in male C57BL/6J mice. After completing a 8-week period of experimentation, the mice were sacrificed 1 hr after the last DA-11004 treatment and their blood, liver, and adipose tissues (epididymal and retroperitoneal fat) were collected. There was a significant difference in the pattern of increasing body weight between the HF control and the DA-11004 group. In the DA-11004 (100 mg/kg) treated group the increase in body weight significantly declined and a content of epididymal fat and retroperitoneal fat was also significantly decreased as opposed to the HF control. DA-11004 (100 mg/ kg) inhibited the IDPc activity, and thus, NADPH levels in plasma and the levels of free fatty acid (FFA) or glucose in plasma were less than the levels of the HF control group. In conclusion, DA-11004 inhibited the fatty acid synthesis in adipose tissues via IDPc inhibition, and it decreased the plasma glucose levels and FFA in HF diet-induced obesity of C57BL/6J mice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0253-6269
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
48-52
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:14969338-Adipose Tissue, pubmed-meshheading:14969338-Animals, pubmed-meshheading:14969338-Blood Glucose, pubmed-meshheading:14969338-Body Weight, pubmed-meshheading:14969338-Diabetes Mellitus, Experimental, pubmed-meshheading:14969338-Dietary Fats, pubmed-meshheading:14969338-Dietary Sucrose, pubmed-meshheading:14969338-Disease Models, Animal, pubmed-meshheading:14969338-Drug Evaluation, Preclinical, pubmed-meshheading:14969338-Epididymis, pubmed-meshheading:14969338-Fatty Acids, Nonesterified, pubmed-meshheading:14969338-Hypoglycemic Agents, pubmed-meshheading:14969338-Isocitrate Dehydrogenase, pubmed-meshheading:14969338-Liver, pubmed-meshheading:14969338-Male, pubmed-meshheading:14969338-Mice, pubmed-meshheading:14969338-Mice, Inbred C57BL, pubmed-meshheading:14969338-Mice, Obese, pubmed-meshheading:14969338-Naphthoquinones, pubmed-meshheading:14969338-Peritoneum, pubmed-meshheading:14969338-Time Factors, pubmed-meshheading:14969338-Triglycerides
pubmed:year
2004
pubmed:articleTitle
Anti-diabetic effects of DA-11004, a synthetic IDPc inhibitor in high fat high sucrose diet-fed C57BL/6J mice.
pubmed:affiliation
Research Laboratories, Dong-A Pharm. Co. Ltd. 47-5, Sanggal, Kiheung, Yongin, Kyunggi 449-900, Korea. pharm91@donga.co.kr
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't